Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Antibodies And Coronavirus – It’s Complicated

Monoclonal Antibodies Have A Poor Antiviral Track Record

Executive Summary

The use of antibodies in disease prevention and treatment is now ingrained in modern medicine but as antiviral agents their record is at best patchy and the reliance on them to treat or prevent coronavirus infections is perhaps premature.

You may also be interested in...



Coronavirus Update: BARDA Funds AstraZeneca Antibody Research

Also: remdesivir filed in the EU.

Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

Stockwatch: Details Differ Between Pfizer And AstraZeneca's Second-Quarter Earnings Reports

Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel